Search results
3 Meme Stocks That Are Likely to Crater in 2024
InvestorPlace· 4 days agoMeme stocks have the potential to completely change the portfolio health even with a limited exposure of 5% to 10%. At the same time, there are meme...
The AstraZeneca vaccine – should you be worried?
Daily Telegraph· 7 days agoEarlier this week, the European Commission announced that the Covid-19 vaccine, developed as part of a collaboration between the British pharma company...
Circular RNA: Vaccines, therapeutics and biomarkers could be revolutionised
Clinical Trials Arena via Yahoo Finance· 3 days agoCircRNA is still in very early days of development, but it is expected to trialled in vaccines,...
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 2 days agoSAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives
Predictive Oncology Inc (POAI) (Q1 2024) Earnings Call Transcript Highlights: Navigating ...
GuruFocus.com via Yahoo Finance· 2 days agoThis opens opportunities for digital pathology applications, efficient clinical trial designs, and direct involvement in drug discovery. Q: Can you discuss ...
Health Benefits of Gelatin
Health via Yahoo News· 3 days agoGelatin may help improve bone and muscle conditions, boost your skin health, and support your gut. However, research on this ingredient is still limited.
The AstraZeneca vaccine – should you be worried?
The Telegraph via Yahoo News· 7 days agoEarlier this week, the European Commission announced that the Covid-19 vaccine, developed as part of a collaboration between the British pharma company...
A Novel Broad-Spectrum Antiviral with Activity Against RSV
Digital Journal· 4 days agoSHELTON, CT / ACCESSWIRE / May 14, 2024 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company"), a global leader in broad-spectrum antiviral nanomedicines, says that antiviral activity of NV ...
Novavax Stock Just Tripled. Is It Too Late to Buy? | The Motley Fool
The Motley Fool· 3 days agoAfter losing more than 90% of its value from a peak back in 2021, Novavax (NVAX -4.30%) stock has...
Hospital care is leaving the hospital
Politico· 4 days agoAnd if the U.S. moves first? Thirstrup said the EU would consider looking at the clinical data under FDA review but wouldn’t simply “take the potential...
